title: Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study.
abstract: BACKGROUND
  We evaluated the long-term results of radiotherapy for patients with gastric marginal zone lymphoma (GMZL).
  
  
  METHODS
  We carried out a retrospective, multi-centre study of patients with low-grade GMZL treated by radiotherapy between 17 July 1981 and 25 March 2004.
  
  
  RESULTS
  There were 102 eligible patients. Fifty-eight patients were previously untreated and 44 had recurrent/residual disease after prior treatment (HP eradication, chemotherapy and surgery in 35, 9 and 8 patients, respectively, and 7 had >1 prior therapy). Radiation fields included the stomach /involved nodes in 61 patients and whole abdomen in 41. The median radiotherapy dose to stomach was 40 Gy (range 26-46 Gy) in a median 22 fractions. With a median follow-up after radiotherapy of 7.9 years (range 0.3-24 years), 10- and 15-year freedom from treatment failure (FFTF) was 88% (95% CI 82%-95%). Risk factors for TF were a large-cell component (P = 0.036) and an exophytic growth pattern (P = 0.042). Radiotherapy field size, radiotherapy dose, and failure of prior therapy were not associated with inferior FFTF. Ten-year overall survival was 70% (95% CI 60%-82%).
  
  
  CONCLUSIONS
  Radiotherapy achieves cure for the majority of patients with low-grade GMZL, including patients who have had prior therapy. Several features may predict a poorer outcome.
authors.affiliation: Division Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, East Melbourne and University of Melbourne, Parkville, Victoria, Australia. andrew.wirth@petermac.org
authors.forename: A
authors.initials: A
authors.lastname: Wirth
authors.forename: M
authors.initials: M
authors.lastname: Gospodarowicz
authors.forename: B M P
authors.initials: BM
authors.lastname: Aleman
authors.forename: M
authors.initials: M
authors.lastname: Bressel
authors.forename: A
authors.initials: A
authors.lastname: Ng
authors.forename: M
authors.initials: M
authors.lastname: Chao
authors.forename: R T
authors.initials: RT
authors.lastname: Hoppe
authors.forename: C
authors.initials: C
authors.lastname: Thieblemont
authors.forename: R
authors.initials: R
authors.lastname: Tsang
authors.forename: L
authors.initials: L
authors.lastname: Moser
authors.forename: L
authors.initials: L
authors.lastname: Specht
authors.forename: T
authors.initials: T
authors.lastname: Szpytma
authors.forename: A
authors.initials: A
authors.lastname: Lennard
authors.forename: J F
authors.initials: JF
authors.lastname: Seymour
authors.forename: E
authors.initials: E
authors.lastname: Zucca
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000401:mortality* / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000401:mortality* / Q000532:radiotherapy*; D016896:Treatment Outcome; D055815:Young Adult